The Military HIV Research Program ( MHRP ) Clinical Trial Unit

军事艾滋病毒研究计划 ( MHRP ) 临床试验单位

• 批准号: 10563429
• 负责人: Julie A. Ake
• 金额: $ 4.28万
• 依托单位: HENRY M. JACKSON FDN FOR THE ADV MIL/MED
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-02-11 至 2022-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10563429
• 关键词: 2019-nCoV; Amendment; COVID-19 vaccine; Centers for Disease Control and Prevention (U.S.); Clinical; Clinical Research; Clinical Trials Network; Clinical Trials Unit; Consultations; Elements; Funding; Future; Group Meetings; HIV; HIV Vaccine Trials Network; Leadership; Military Personnel; Modality; Monoclonal Antibodies; National Institute of Allergy and Infectious Disease; Outcome; Prevention; Research; Role; Testing; United States National Institutes of Health; VTN gene; Vaccines; clinical development; coronavirus disease; meetings; novel; pre-clinical; programs; research and development; vaccine development; vaccine-induced antibodies

Abstract COVID-19 Vaccine Clinical Development Team The USG enterprise to develop and optimize vaccine prevention modalities for SARS CoV-2 incorporates the DAIDS HVTN as a key partner in strategic development, research prioritization and execution, landscape analysis for future directions and analysis of outcomes. Dr. Robb has co-chaired and participated in the USG Vaccine Development Team for clinical research along with the PI and others within the HVTN. The administrative amendment to CTU funding to HJF will sustain Dr. Robb’s role in this capacity.

抽象的 COVID-19疫苗临床开发团队 USG 企业开发和优化 SARS CoV-2 疫苗预防方式包括 DAIDS HVTN 作为战略发展、研究优先顺序和执行的关键合作伙伴， 罗布博士担任联合主席和成果分析。 与PI等人一起参与USG疫苗开发团队的临床研究 对 CTU 向 HJF 提供资金的行政修订将维持 Robb 博士在 HVTN 中的作用。 这个能力。